Abstract 436P
Background
AYA melanomas (diagnosed 16-39 years) are rare but rising in incidence. It is not well-understood how they differ from adult melanomas. We aim to describe the demographics, clinic-molecular characteristics and outcomes from our institution.
Methods
We retrospectively reviewed all melanoma patients diagnosed between 16 and 39 years old (y) who presented to the National Cancer Centre Singapore from 1 January 2000 to 31 March 2019.
Results
There were 74 patients (41 females, 33 males). 51.4% (n=38) were Chinese, 9.5% Caucasians, 6.8% Malays and the rest of other ethnicity. Across age groups, 9 patients were 16-23 y (12.2%); 26 between 24-31y (35.1%) and 39 between 32-39y (52.7%). The most common subtype was cutaneous melanoma (46%, n=34). 31 (41.9%) patients had BRAF testing. 46.4% (n=13) had BRAF V600E mutation and 1 had BRAF V600K. 20 (27.0%) were tested for cKIT, with none having mutations. 51.4% (n=38) had stage I/II disease (American Joint Committee on Cancer 7th Edition), 16 with stage III and 10 had stage IV. Common metastatic sites were lungs, lymph nodes and liver. 25 (33.8%) patients had sentinel lymph node biopsy (SLNBx), with 5 having lymph node dissection. Among those with SLNBx, 4, 13 and 5 patients had Breslow depths of <1mm, 1-4mm and >4mm respectively. The median depth was 2.7mm (range 0.25–9mm). 7 (9.5%) had first-line systemic therapy, with 5 (2 stage IV; 2 stage III and 1 unknown) receiving immunotherapy. 2 (stage IV) had combination chemotherapy (Dacarbazine/Cisplatin and Paclitaxel/Bevacizumab/Caroboplatin). None received BRAF inhibitors. The median overall survival (OS) is 2.7y (range 0.1–17.7y) for all and 1y for metastatic disease. The 5y OS is 34.5%. The breakdown is shown in the table. Table: 436P
Survival by age and stage
Number | Median OS | p-value | |
16-23y | 9 | 4.53 | =0.15 |
24-31y | 26 | 4.15 | |
32-39y | 39 | 2.51 | |
Stage I-III | 54 | 3.25 | <0.001 |
Stage IV | 10 | 1.01 |
Conclusions
Routine BRAF/cKIT testing commenced in 2010 and immunotherapy started only in 2017, contributing to outcomes we see. Poorer survival is associated with higher stage (p<0.001). Further studies are needed to elucidate potential biological and cancer-specific differences between AYAs and adult melanoma population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session